spacer
home > white papers > The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation - BioPharmaSpec
WHITE PAPERS
logo_BioPharmaS.jpg

BioPharmaSpec

phone +1 610-640-5866
email services.usa@biopharmaspec.com
web http://biopharmaspec.com
email BioPharmaSpec Inc 363 Phoenixville Pike Malvern, PA 19355 USA

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

1. Introduction

As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

The Native Antigen Company Introduces New Range of Influenza Antigens

Oxford, UK, 16 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season. The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure public safety throughout the annual flu season.
More info >>


White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement